Afelimomab
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Afelimomab?
| |
| Therapeutic monoclonal antibody | |
| Source | Mouse |
| Target | TNFα |
| Identifiers | |
| CAS number | |
| ATC code | L04 |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
Mouse monoclonal antibodies ("-o-") | |
|---|---|
| "govo" (ovarian tumor) | Abagovomab, Igovomab, Oregovomab |
| "limo" (immune system) | Afelimomab, Dorlimomab aritox, Elsilimomab, Faralimomab, Gavilimomab, Inolimomab, Maslimomab, Nerelimomab, Odulimomab, Telimomab aritox, Vepalimomab, Zolimomab aritox |
| "tumo" (miscellaneous tumor) | Altumomab, Anatumomab mafenatox, Arcitumomab, Bectumomab, Detumomab, Epitumomab, Epitumomab cituxetan, Ibritumomab tiuxetan, Minretumomab, Mitumomab, Naptumomab estafenatox, Nofetumomab merpentan, Pemtumomab, Pintumomab, Satumomab, Taplitumomab paptox, Tositumomab |
| "leso" (infectious lesions) | Besilesomab, Fanolesomab, Lemalesomab, Sulesomab |
| "ciro" (cardiovascular) | Biciromab brallobarbital, Imciromab |
| "pro" (prostate tumor) | Capromab |
| "baco" (bacterial) | Edobacomab |
| "colo" (colonic tumor) | Edrecolomab, Nacolomab tafenatox |

